s:**
- Compare tau strain spreading in EXT1/EXT2 conditional knockout mice
- Test whether HSPG-deficient astrocytes still form tufts vs plaques when e
Background and Rationale
This experiment investigates the role of heparan sulfate proteoglycans (HSPGs) in tau strain propagation by examining conditional knockout mice lacking EXT1/EXT2, enzymes essential for HSPG synthesis. The scientific rationale stems from growing evidence that HSPGs serve as cofactors for tau seeding and spreading between neurons, potentially explaining strain-specific pathological patterns observed in different tauopathies. Using astrocyte-specific conditional knockout models, this study will compare how different tau strains (such as those associated with Alzheimer's disease versus frontotemporal dementia) propagate in the absence of functional HSPGs. The experimental approach involves stereotactic injection of distinct tau strains into the hippocampus of GFAP-Cre; EXT1/EXT2 floxed mice, followed by longitudinal assessment of tau pathology spreading patterns using immunohistochemistry and biochemical analysis. The study will specifically examine whether HSPG-deficient astrocytes still form characteristic astrocytic tau tufts versus neuritic plaques, addressing fundamental questions about the molecular mechanisms underlying strain-specific tau propagation. This research could reveal critical insights into how extracellular matrix components influence neurodegenerative disease progression and identify potential therapeutic targets for controlling pathological protein spreading.
This experiment directly tests predictions arising from the following hypotheses:
- LRP1-Dependent Tau Uptake Disruption
- TREM2-mediated microglial tau clearance enhancement
- Noradrenergic-Tau Propagation Blockade
- HSP90-Tau Disaggregation Complex Enhancement
- Synaptic Vesicle Tau Capture Inhibition
Experimental Protocol
Phase 1: Animal Preparation and Genotyping (Weeks 1-2)• Generate EXT1/EXT2 floxed mice crossed with GFAP-Cre or Aldh1l1-Cre lines for astrocyte-specific conditional knockout (n=60 total)
• Genotype all animals using PCR with primers for floxed alleles and Cre recombinase
• Randomly assign to groups: Control (Cre-negative, n=15), EXT1 cKO (n=15), EXT2 cKO (n=15), EXT1/EXT2 double cKO (n=15)
• Age mice to 8-10 weeks for baseline mature astrocyte populations
Phase 2: Tau Strain Preparation and Stereotactic Injection (Week 3)
• Prepare recombinant PSP-tau and CBD-tau fibrils at 2 μg/μL concentration
• Perform stereotactic injection into hippocampus (AP: -2.0mm, ML: ±1.5mm, DV: -1.8mm)
• Inject 2 μL of tau fibrils unilaterally, contralateral hemisphere receives vehicle control
• Post-surgical monitoring for 7 days with analgesics as needed
Phase 3: Pharmacological HSPG Degradation Treatment (Weeks 4-8)
• Administer heparinase III (10 U/kg) via intracerebroventricular injection weekly to subset of animals (n=7-8 per genotype)
• Control groups receive vehicle injections on same schedule
• Monitor body weight and neurological scores weekly using modified SHIRPA protocol
Phase 4: Tissue Collection and Processing (Weeks 12-16)
• Sacrifice animals at 4, 8, and 12 weeks post-injection (n=5 per timepoint per group)
• Transcardial perfusion with 4% paraformaldehyde
• Cryosection brains at 40 μm thickness for immunohistochemistry
• Flash-freeze tissue samples for biochemical analysis
Phase 5: Immunohistochemical Analysis (Weeks 17-20)
• Stain sections with PHF-1 (phospho-tau), GFAP (astrocytes), and HSPG-specific antibodies
• Quantify tau pathology spread using stereological methods in 6 brain regions
• Classify astrocyte morphology as tufted vs plaque-like using established criteria
• Measure astrocyte HSPG expression levels via fluorescence intensity quantification
Expected Outcomes
Reduced tau pathology spreading: EXT1/EXT2 cKO mice will show 40-60% reduction in tau-positive neurons compared to controls at 8-12 weeks post-injection (p<0.01).
Altered astrocyte tau morphology: HSPG-deficient astrocytes will show significantly reduced tufted astrocyte formation (>70% reduction) when exposed to PSP tau strains, with maintenance of plaque-like morphology.
Strain-specific differential effects: CBD tau will show greater dependence on HSPGs for spreading compared to PSP tau, with 2-3 fold difference in reduction between strains in cKO animals.
Pharmacological validation: Heparinase III treatment will phenocopy genetic knockout effects, reducing tau pathology by 35-50% compared to vehicle-treated controls.
Regional spreading pattern changes: Anterograde tau spreading to CA3 and entorhinal cortex will be reduced by 50-70% in HSPG-deficient animals compared to controls.
Compensatory HSPG upregulation: Remaining astrocytes in single knockout animals will show 1.5-2 fold upregulation of non-targeted HSPG biosynthesis genes.Success Criteria
•
Statistical significance threshold: Primary endpoints must achieve p<0.01 with effect sizes (Cohen's d) >0.8 for tau pathology reduction between genotypes
• Minimum sample size validation: At least 80% of planned animals per group (n≥12/15) must survive to final timepoints for valid statistical analysis
• Knockout efficiency confirmation: >85% reduction in target HSPG expression must be confirmed by qRT-PCR and immunofluorescence in astrocytes from cKO animals
• Morphological classification reliability: Inter-rater agreement >90% for tufted vs plaque-like astrocyte classification using established morphometric criteria
• Pharmacological validation concordance: Heparinase III effects must show same directional changes as genetic knockouts with overlapping 95% confidence intervals
• Regional specificity confirmation: Significant effects must be observed in at least 4/6 analyzed brain regions with consistent directional changes across regions